ReviewJournal of endocrinological investigation2012
Familial isolated pituitary adenomas: an emerging clinical entity.
Review in Journal of endocrinological investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- The Clinicopathological Spectrum of Acromegaly.Journal of clinical medicine · 2019Review
- The causes and consequences of pituitary gigantism.Nature reviews. Endocrinology · 2018Review
- Article
- Somatotroph-SpecificJournal of the Endocrine Society · 2017Article
- Article
- Skin manifestations of growth hormone-induced diseases.Reviews in endocrine & metabolic disorders · 2016Review
- Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant?Pituitary · 2015Article
- Rare diseases in clinical endocrinology: a taxonomic classification system.Journal of endocrinological investigation · 2015Article
- Genetic mutations in sporadic pituitary adenomas--what to screen for?Nature reviews. Endocrinology · 2015Review
- Progress in the Diagnosis and Classification of Pituitary Adenomas.Frontiers in endocrinology · 2015Review
- A novel germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene in an Italian family with gigantism.Journal of endocrinological investigation · 2014Article
- A novel C-terminal nonsense mutation, Q315X, of the aryl hydrocarbon receptor-interacting protein gene in a Japanese familial isolated pituitary adenoma family.Endocrine pathology · 2014Article
- The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas.Endocrine · 2014Review
- Genetics of gigantism and acromegaly.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial pituitary tumors are increasingly recognized. While some of these cases are related to wellknown syndromic conditions such as multiple endocrine neoplasia type 1 (MEN1) or Carney complex, others belong to the familial isolated pituitary adenoma (FIPA) patient group. The discovery of heterozygous, loss-of-function germline mutations in the gene encoding the aryl hydrocarbon receptor interacting protein (AIP) in 2006 has subsequently enabled the identification of a mutation in this gene in 20% of FIPA families and 20% of childhood-onset simplex soma- totroph adenomas. The exact mechanism by which the lack of AIP leads to pituitary adenomas is not clear. AIP mutations cause a low penetrance autosomal dominant disease with often a distinct phenotype characterized by young-onset, aggressive, large GH, mixed GH and PRL or PRL-secreting adenomas. This review aims to summarize currently available clinical data on AIP mutation-positive and negative FIPA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.